Anthropic closes IPO of 1.127bln Class A shares at USD 83, including full exercise of the underwriters’ option
Newsquawk Staff ·
- Receives USD 91.6bln from IPO; total gross proceeds of USD 93.5bln.
- Did not receive any proceeds from sale of shares by the selling stockholders.
What it means
Full exercise of the underwriters' overallotment option is the standard tell that book demand covered the deal at price: greenshoes get exercised when the aftermarket holds at or above the offer, and large-cap tech listings that clear with the shoe filled have historically traded differently from those that limp through, with the former tending to see the option itself act as short-term price support before expiry. The proceeds split is the other structural point: primary capital accrues to the balance sheet, while the selling-stockholder tranche represents existing holders monetising, and deals weighted toward secondary have tended to carry heavier insider-supply overhang once restrictions lapse. The calendar that matters from here is conventional: the quiet period end for underwriter initiation, the lockup expiry which historically concentrates supply risk in venture and employee-heavy registers, and any index inclusion mechanics that force passive buying irrespective of fundamentals. For a listing of this scale, the peer-set read-across is to prior mega-cap technology floats, where post-pricing performance has tended to hinge less on the debut and more on the first earnings print against an unseasoned consensus. What is worth watching is aftermarket stability through the stabilisation window and any early disclosure on float composition.
- FTSE Russell says Anthropic (ANT) will be a fast entry to the FTSE Global Equity Index Series
- MSCI to add Anthropic to large‑cap segment of MSCI Global Standard Indexes on November 30th
- Intuit Inc. (INTU) Q1 FY27 (USD): Adj. EPS 2.91 (exp. 2.46), Revenue 4.4bln (exp. 4.3bln); Agrees to sell Mailchimp to Bending Spoons (BSP) for around USD 3.68bln, made up of USD 3.31bln in cash and USD 368mln in Bending Spoons stock
- Anthropic (ANT) shares open at USD 111.50/shr (vs. IPO price of USD 83/shr)
- Anthropic (ANT) shares indicated to open at USD 110.50 in Nasdaq debut (vs IPO price USD 83/shr)
Related headlines
- Anthropic (ANT) shares indicated to open at USD 111 in Nasdaq debut (IPO price USD 83/shr); CNBC says over 10% of offering size volume has been traded, indicating it could open any minute20 hours ago
- Nvidia (NVDA) and Microsoft (MSFT) to roll out Vera Rubin NVL72 on Azure; Vera Rubin NVL72 systems are now operating in Azure data centres16 hours ago
- US FX WRAP: Dollar gains in risk-off trade; AUD hit on poor jobs report16 hours ago
- [MARKET ANALYSIS] Fixed firmer as energy falters and the risk tone remains negative3 hours ago
- US Market Wrap: Risk sentiment swings to Anthropic IPO15 hours ago
- Fed's Goolsbee says he doesn't see inflation on a path back to 2% at this point, as it isn't just coming from oil and tariff shocks but has a sizeable demand component16 hours ago
- [MARKET UPDATE]: T-note futures catch bid around settlement while ANT shares fall further; Dollar and stocks move lower17 hours ago
- Newsquawk Daily European Equity Opening News - 20th November 20266 hours ago
- [MARKET UPDATE] Asia-Pac stocks are lower following the broad risk-off mood on Wall St where the major indices fell over 2%, despite Anthropic rallying in its record debut12 hours ago
- TREASURY WRAP: T-NOTE FUTURE (Z6) SETTLES 3 TICKS HIGHER AT 105-2816 hours ago
- PayPal (PYPL) announces several executive leadership appointments to advance its three-year strategy31 min ago
- PayPal (PYPL) appoints former Goldman Sachs (GS) CRO Brian J. Lee to its board, effective November 30th50 min ago
- Yemeni spokesperson says they do declare that the financial centers in the King Abdullah Economic City are now a military target1 hour ago
- Italy has approved Tesla's (TSLA) self-driving system1 hour ago
- Merck & Co. (MRK) says Phase 3 TroFuse-015 trial of sac-TMT improved overall survival in advanced gastroesophageal adenocarcinoma but did not meet its progression-free survival endpoint1 hour ago